Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus
Nihal C. de Lanerolle(Yale University), Michael Brines(Northwell Health), Anne Williamson, Herriot Tabuteau(Axsome Therapeutics (United States)), C. N. Meredith(Yale University), Dennis D. Spencer(Boston Children's Hospital), J.H Kim(Yale University)
Cited by 57
Related Papers
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
|Proceedings of the National Academy of Sciences|2000|1.4k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor
|Proceedings of the National Academy of Sciences|2004|654